N-{3-[(3R)-5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl]phenyl}-5-chloropyridine-2-carboxamide | 1266786-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{3-[(3R)-5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl]phenyl}-5-chloropyridine-2-carboxamide
• 英文别名: (R)-N-(3-(5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)phenyl)-5-chloropyridine-2-carboxamide；(R)-5-chloro-pyridine-2-carboxylic acid [3-(5-amino-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-phenyl]-amide；(R)-N-[3-(5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl)phenyl]-5-chloropyridine-2-carboxamide；N-[3-[(3R)-5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl]phenyl]-5-chloropyridine-2-carboxamide
• CAS: 1266786-47-3
• 化学式: C₁₇H₁₇ClN₄O₂
• 分子量: 344.801
• InChiKey: ZZUPAAPYPBQGKS-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-2-(3-溴苯基)丙酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) 二苯甲酮亚胺 、 lithium aluminium tetrahydride 、 tetraphosphorus decasulfide 、 氨 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二甲基苯胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 二氧化碳 、 水 、 甲苯 为溶剂， 反应 26.33h， 生成 N-{3-[(3R)-5-amino-3-methyl-3,6-dihydro-2H-1,4-oxazin-3-yl]phenyl}-5-chloropyridine-2-carboxamide
  参考文献：
  名称：

  [EN] 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
  [FR] DÉRIVÉS DE 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YLAMINE UTILES COMME INHIBITEURS DE BÊTA-SÉCRÉTASE (BACE)

  摘要：

  本发明涉及新型5,6-二氢-2H-[1,4]噁唑啉-3-胺衍生物，作为β-分泌酶抑制剂，也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及用于预防和治疗涉及β-分泌酶的疾病的这些化合物和组合物的用途，如阿尔茨海默病（AD）、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、唐氏综合征、与中风相关的痴呆、与帕金森病相关的痴呆以及与β-淀粉样蛋白相关的痴呆。

  公开号：

  WO2011154431A1

文献信息

• 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES
  申请人：Andreini Matteo

  公开号：US20110046122A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的化学式I的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪，以及它们的制备、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面具有用途。
• [EN] 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-AMINO-5-PHÉNYL-5,6-DIHYDRO-2H-[1,4]OXAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011020806A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[l,4]oxazine derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式(I)的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪衍生物，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面是有用的。
• A practical entry to β-aryl-β-alkyl amino alcohols: application to the synthesis of a potent BACE1 inhibitor
  作者：Oscar Delgado、Antonio Monteagudo、Michiel Van Gool、Andrés A. Trabanco、Santos Fustero

  DOI：10.1039/c2ob25845e

  日期：——

  The 1,2-addition of alkyl Grignard reagents to readily available N-tert-butanesulfinyl ketimines, bearing an α-silyloxy substituent, proceeds in high yields and excellent diastereocontrol. The utility of the present method was demonstrated by the synthesis, in enantiomerically pure form, of one recently disclosed β-secretase (BACE1) inhibitor.

  将烷基格氏试剂与容易获得的带有δ-硅氧基取代基的 N-叔丁基亚磺酰亚胺进行 1,2 加成，产量高，非对映控制极佳。最近公开的一种δ-分泌酶（BACE1）抑制剂的对映体纯合成证明了这种方法的实用性。
• 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130196984A1

  公开（公告）日：2013-08-01

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及公式I的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁唑烷，具有BACE1和/或BACE2抑制活性，其制造方法，含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防例如阿尔茨海默病和2型糖尿病方面非常有用。
• 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads
  作者：Frederik J. R. Rombouts、Gary Tresadern、Oscar Delgado、Carolina Martínez-Lamenca、Michiel Van Gool、Aránzazu García-Molina、Sergio A. Alonso de Diego、Daniel Oehlrich、Hana Prokopcova、José Manuel Alonso、Nigel Austin、Herman Borghys、Sven Van Brandt、Michel Surkyn、Michel De Cleyn、Ann Vos、Richard Alexander、Gregor Macdonald、Dieder Moechars、Harrie Gijsen、Andrés A. Trabanco

  DOI：10.1021/acs.jmedchem.5b01101

  日期：2015.10.22

  1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays. We describe lead optimization focused on reducing the amidine pK(a) while optimizing interactions in the BACE1 active site. Our strategy permitted modulation of properties such as permeation and especially P-glycoprotein efflux. This led to compounds which were orally bioavailable, centrally active, and which demonstrated robust lowering of brain and CSF A beta levels, respectively, in mouse and dog models. The amyloid lowering potential of these molecules makes them valuable leads in the search for new BACE1 inhibitors for the treatment of Alzheimer's disease.